Viewing Study NCT06614192


Ignite Creation Date: 2025-12-24 @ 3:51 PM
Ignite Modification Date: 2026-02-03 @ 1:45 AM
Study NCT ID: NCT06614192
Status: RECRUITING
Last Update Posted: 2025-08-26
First Post: 2024-09-25
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Sponsor: AbbVie
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Colorectal Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Metastatic Colorectal Cancer View
None Telisotuzumab Adizutecan View
None ABBV-400 View
None Trifluridine View
None Tipiracil View
None LONSURF View
None Bevacizumab View
None AndroMETa-CRC-064 View